ангиотензин转化酶和心脏衰竭
Sara Álvarez-Zaballos1, Manuel Martínez-Sellés1,2,3
1Cardiology Department, Hospital General Universitario Gregorio Marañón, CIBERCV, 28007 Madrid, Spain.
Frontiers in bioscience (Landmark edition)
|August 1, 2023
概括
本综述涵盖了针对宁- ангиотензин- 阿尔多斯特系统 (RAAS) 的药物如何治疗心力衰竭 (HF). 它详细介绍了RAAS病理生理学,神经激素变化,以及在高血压管理中ACE抑制剂,ARB和ARNI的证据.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物医学科学 生物医学科学
背景情况:
- 心力衰竭 (HF) 的管理严重依赖于药物治疗.
- 氨酸- ангиотензин- алдостерон系统 (RAAS) 在HF病理生理学中起着至关重要的作用.
- 神经激素失调是心力衰竭的一个标志.
研究的目的:
- 审查心力衰竭中RAAS的病理生理学.
- 讨论针对RAAS的药物的作用机制.
- 总结这些药物在HF患者中的临床证据.
主要方法:
- 关于RAAS病理生理学和HF的文献综述.
- 对药物类别的分析:ACE抑制剂,ARBs和ARNI (萨库比特里尔/瓦尔萨坦).
- 对心力衰竭中药物疗效的证据的评估.
主要成果:
- 激活RAAS有助于心脏重塑和功能障碍在HF.
- ACE 抑制剂,ARB 和 ARNI 调节 RAAS 以改善 HF 结果.
- 有证据支持使用这些药物来降低HF发病率和死亡率.
结论:
- 针对RAAS的药物治疗对于心力衰竭治疗至关重要.
- 了解RAAS病理生理学指导选择有效的HF药物.
- 包括ARNI在内的ACE相关药物对于治疗心力衰竭患者至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
692
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
692
Heart Failure I: Introduction
16
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
16
Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13


